Erratum: Protocol for a randomised controlled trial: efficacy of donepezil against psychosis in Parkinson's disease (EDAP) (BMJ Open (2013) 3 (e003533) DOI: 10.1136/BMJOPEN-2013-003533);Protocol for a randomised controlled trial: Efficacy of donepezil against psychosis in Parkinson's disease (EDAP)

BMJ Open

Volumn 3, Issue 9, 2013, Pages

  Sawada, Hideyuki ^a   Oeda, Tomoko ^a  

^a UTANO NATIONAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; PLACEBO;

AGGRESSION; ARTICLE; CLINICAL EVALUATION; CLINICAL PROTOCOL; CONTROLLED STUDY; COOPERATION; DELUSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EMOTIONAL STRESS; HALLUCINATION; HUMAN; INFORMED CONSENT; INTENTION TO TREAT ANALYSIS; LOG RANK TEST; MULTICENTER STUDY; OUTCOME ASSESSMENT; PARKINSON DISEASE; PARKINSON PSYCHOSIS QUESTIONNAIRE; PSYCHOSIS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; SOCIAL ENVIRONMENT; UNIFIED PARKINSON DISEASE RATING SCALE; WELLBEING;

EID: 84885352356     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/BMJOPEN-2013-003533CORR1     Document Type: Erratum

References (23)

1. Adler CH. Nonmotor complications in Parkinson's disease. Mov Disord 2005;20(Suppl 11):S23-9. (Pubitemid 40846908)
2. Maetzler W, Liepelt I, Berg D. Progression of Parkinson's disease in the clinical phase: potential markers. Lancet Neurol 2009;8:1158-71.
3. Clozapine in drug-induced psychosis in Parkinson's disease. The French Clozapine Parkinson Study Group. Lancet 1999;353:2041-2.
4. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. The Parkinson Study Group. N Engl J Med 1999;340:757-63.
5. Breier A, Sutton VK, Feldman PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry 2002;52:438-45. (Pubitemid 35266735)
6. Ondo WG, Tintner R, Voung KD, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 2005;20:958-63. (Pubitemid 41419510)
7. Rabey JM, Prokhorov T, Miniovitz A, et al. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. Mov Disord 2007;22:313-18. (Pubitemid 46569682)
8. Ellis T, Cudkowicz ME, Sexton PM, et al. Clozapine and risperidone treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2000;12:364-9. (Pubitemid 30665218)
9. Mesulam MM. Alzheimer plaques and cortical cholinergic innervation. Neuroscience 1986;17:275-6.
10. Whitehouse PJ, Price DL, Clark AW, et al. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981;10:122-6. (Pubitemid 11053099)
11. Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003;60:1745-8. (Pubitemid 37521630)
12. Jellinger KA. Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol 1991;14:153-97.
13. Goetz CG, Leurgans S, Pappert EJ, et al. Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology 2001;57:2078-82. (Pubitemid 33126877)
14. Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. Lancet Neurol 2005;4:605-10. (Pubitemid 41317294)
15. Merims D, Shabtai H, Korczyn AD, et al. Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease. J Neural Transm 2004;111:1447-53. (Pubitemid 39468398)
16. Kawakami Y, Inoue A, Kawai T, et al. The rationale for E2020 as a potent acetylcholinesterase inhibitor. Bioorg Med Chem 1996;4:1429-46. (Pubitemid 26319994)
17. Giacobini E, Zhu XD, Williams E, et al. The effect of the selective reversible acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex. Neuropharmacology 1996;35:205-11. (Pubitemid 26082121)
18. Nochi S, Asakawa N, Sato T. Kinetic study on the inhibition of acetylcholinesterase by 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl] methylpiperidine hydrochloride (E2020). Biol Pharm Bull 1995;18:1145-7.
19. Kosasa T, Kuriya Y, Matsui K, et al. Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats. Eur J Pharmacol 1999;380:101-7. (Pubitemid 29469519)
20. Kosasa T, Kuriya Y, Yamanishi Y. Effect of donepezil hydrochloride (E2020) on extracellular acetylcholine concentration in the cerebral cortex of rats. Jpn J Pharmacol 1999;81:216-22. (Pubitemid 29532981)
21. Manganelli F, Vitale C, Santangelo G, et al. Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson's disease. Brain 2009;132(Pt 9):2350-5.
22. Brandstaedter D, Spieker S, Ulm G, et al. Development and evaluation of the Parkinson Psychosis Questionnaire a screening-instrument for the early diagnosis of drug-induced psychosis in Parkinson's disease. J Neurol 2005;252: 1060-6. (Pubitemid 41355836)
23. Daniel SE, Lees AJ. Parkinson's Disease Society Brain Bank, London: overview and research. J Neural Transm 1993;39: 165-72. (Pubitemid 23216938)